Late Breaking Abstract - Anti-inflammatory activity of novel transtilbene sulfonamide analogues as potential novel therapeutic agents for inflammatory lung disease

Oxidative stress plays an important role in the pathogenesis of chronic obstructive pulmonary disease (COPD). COPD is one of the leading causes of mortality in the UK. Current treatment options for COPD are limited and do not prevent disease progression. Hence, there is an urgent requirement for alternative novel therapeutic approaches. Stilbenoid natural products, including trans-resveratrol and synthetic analogues have demonstrated a variety of biological properties, in particular anti-oxidant and anti-inflammatory properties. Cell health assessments were carried out using the stilbene sulfonamide compound library (0.1 μM to 100 μM) against 2D human lung airway epithelial/immune cells for their efficacy for use as novel inhalable drugs. Some of the analogues have shown promising anti-oxidant potential in vitro, displaying comparable activity as resveratrol at 10 µM concentrations. In particular compound 6G was observed to possess strong anti-oxidant and anti-inflammatory activity at 10 µM (Figure 1). This library of trans-stilbene sulfonamide analogues warrant further investigation to assess their potential use for airway diseases such as COPD and asthma.